- Raw materials
- Barbiturates
- Methylpentynol
Methylpentynol API Manufacturers & Suppliers
0 verified results
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Methylpentynol | CAS No: 77-75-8 | GMP-certified suppliers
A medication that functions as a central nervous system depressant with sedative and hypnotic properties, primarily intended for experimental and research use in neurological and psychiatric applications.
Therapeutic categories
Product Snapshot
- Methylpentynol is formulated as an oral small molecule
- Its primary therapeutic application is as a central nervous system depressant
- The compound is currently classified as experimental with no approved status in major regulatory markets
Clinical Overview
Pharmacodynamically and in terms of mechanism of action, detailed data for methylpentynol is not currently documented in the literature. Given its classification, it may exert depressant effects on the central nervous system, though the precise molecular targets and pathways remain unspecified.
Key absorption, distribution, metabolism, and excretion (ADME) parameters for methylpentynol have not been elucidated in available sources. Without clinical or preclinical pharmacokinetic data, predictions regarding bioavailability, metabolic pathways, or elimination routes cannot be made.
Safety and toxicity profiles for methylpentynol are likewise poorly characterized. As a CNS depressant and hypnotic agent, caution would be warranted due to risks of sedation, respiratory depression, and potential toxicity with overdose, but definitive toxicological data are lacking. Methylpentynol remains an experimental compound, and it is not currently approved for therapeutic use in any jurisdictions. There are no widely recognized commercial brands or products containing methylpentynol.
From an API procurement perspective, sourcing methylpentynol requires attention to chemical purity, isomeric composition, and compliance with regulatory standards for experimental substances. As no pharmacopeial monographs exist, reliance on validated analytical methods and supplier quality certifications is essential to ensure consistency and safety for investigational or research applications.
Identification & chemistry
| Generic name | Methylpentynol |
|---|---|
| Molecule type | Small molecule |
| CAS | 77-75-8 |
| UNII | B017BC5B1N |
| DrugBank ID | DB13733 |
Formulation & handling
- Methylpentynol is a small molecule suitable for oral formulation due to moderate water solubility and low molecular weight.
- Formulation should consider the alpha,beta unsaturated ketone (ynone) moiety, which may be prone to nucleophilic attack or instability under certain conditions.
- Low LogP indicates moderate lipophilicity, potentially affecting absorption and distribution profiles; optimize excipient selection accordingly.
Regulatory status
Methylpentynol is a type of Barbiturates
Barbiturates are a category of pharmaceutical active pharmaceutical ingredients (APIs) that have sedative, hypnotic, and anticonvulsant properties. They belong to the class of drugs called depressants, which slow down the central nervous system (CNS) activity. Barbiturates have been widely used in the medical field for their ability to induce sleep, reduce anxiety, and control seizures.
The mechanism of action of barbiturates involves enhancing the effects of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) in the brain. GABA inhibits the transmission of signals between nerve cells, leading to relaxation and sedation. Barbiturates bind to specific GABA receptors, increasing the inhibitory effects of GABA and resulting in a calming effect on the CNS.
In the past, barbiturates were commonly prescribed for insomnia, anxiety disorders, and epilepsy. However, their use has decreased significantly due to the emergence of safer and more effective alternatives with fewer side effects. Nonetheless, barbiturates are still utilized in certain medical situations, such as anesthesia induction, emergency seizure control, and in some cases of refractory epilepsy.
Despite their therapeutic benefits, barbiturates carry potential risks and side effects. They can cause drowsiness, impaired coordination, and dependence when used for extended periods. Overdose of barbiturates can be life-threatening, leading to respiratory depression and coma.
In conclusion, barbiturates are a class of API widely known for their sedative, hypnotic, and anticonvulsant properties. While their use has diminished over time, they remain important in specific medical contexts. Proper caution and medical supervision are crucial when using barbiturates to ensure safety and efficacy.
